Study guide

27.2 Audit Trails, Electronic Outcomes and Device Choice

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

27.2 Audit Trails, Electronic Outcomes and Device Choice

Key Takeaways Explain This Topic AI

Audit trails and relevant metadata should remain interpretable and protected.

Rare justified audit-trail corrections require a log of the action and justification.

ePRO timestamps and windows reduce some risks but do not prove who answered or full comprehension.

Last updated: October 2026

Audit Trails, Electronic Outcomes and Device Choice

Relevant metadata explain data context: who or what generated a record, dates/times, workflow, changes and transfers. Plan review and retention based on risk and criticality. A timestamp should be unambiguous, for example using UTC or a clear time-zone convention; UTC is not the only possible implementation.

Systems should retain initial entries and subsequent changes/deletions and capture reasons where appropriate. Audit trails and logs should not be disabled. E6(R3) allows rare justified modification, such as removal of inadvertently entered personal information, only when the action and justification are logged. Therefore, an absolute claim that no administrator can ever modify any audit record is inaccurate. Controlled traceability and protection against inappropriate alteration are the underlying requirements.

Review higher-criticality data and metadata according to the plan. An unusual entry time can reflect a legitimate shift or time-zone difference, not necessarily an unauthorised foreign contractor. Investigate patterns in context and preserve evidence before drawing conclusions.

Anatomy of an EDC Audit Trail Record

Every individual entry in an EDC audit trail contains five traceable data elements:

  • Audit Trail Field Field Description Example Record Entry
  • Timestamp Universal date and exact second of transaction 2026-10-18 14:22:07 UTC
  • Operator Identity Full name, unique user ID, and assigned role Sarah Jenkins, RN (User ID: SJENK_CRC)
  • Action Type Database operation performed UPDATE (Field Edit)

Field & Value Delta Target eCRF form, variable name, and exact change Form: Vitals -> Field: Diastolic_BP -> Old: 98 -> New: 88

  • Reason for Change Documented operator justification Data Query Resolution: Source record verified
  • CRA Audit Trail Review Strategies (E6(R3))

E6(R3) calls for planned risk-based review of relevant data and metadata. The actual monitoring responsibilities and scope should be documented in the trial’s approach. CRAs examine audit trail logs for specific data integrity red flags:

Late Eligibility Adjustments: Alterations to inclusion or exclusion criteria (e.g., baseline lab values or diagnostic scores) executed days after randomization, suggesting that a non-eligible participant was retroactively made eligible.

Post-Hoc Safety Modifications: Downgrading an Adverse Event from "Severe" to "Mild" or altering investigator causality from "Related" to "Unrelated" shortly after sponsor safety communications.

Bulk Data Alterations: Large tranches of data entered or modified minutes before a scheduled monitoring visit or regulatory inspection.

Unusual Working Hours: Extensive data entry or signature execution occurring at 03:00 AM on weekends, warranting contextual review of work patterns, time zones and authorised access.

Direct Electronic Source (eSource), ePRO, eCOA & Wearables

The traditional paradigm where clinical data are recorded on paper medical records and subsequently transcribed into an EDC system introduces human transcription error, operational lag, and duplicate documentation burdens. Direct electronic capture can reduce transcription while still requiring suitable controls over source, metadata, access and transfer.

ePRO and eCOA Modalities

Electronic Clinical Outcome Assessment (eCOA): An umbrella term encompassing clinical assessments captured electronically, including clinician-reported outcomes (ClinRO), observer-reported outcomes (ObsRO), performance outcomes (PerfO), and patient-reported outcomes (ePRO).

Electronic Patient-Reported Outcomes (ePRO): Questionnaires, visual analog scales (VAS), pain scores, and medication adherence logs completed directly by the trial participant using a digital tablet or smartphone.

Elimination of "Parking Lot Syndrome": A notorious deficiency of paper subject diaries is the "parking lot phenomenon," wherein participants neglect daily diary logging for an entire month, sit in the clinic parking lot ten minutes prior to their appointment, and rapidly fabricate thirty days of retrospective symptom entries. Validated ePRO devices eliminate this hazard by utilizing tamper-evident automated timestamps and programmed completion windows (e.g., daily morning symptom questionnaires unlock at 07:00 AM and lock permanently at 10:00 AM, controlling retrospective entry according to the designed process).

Wearable Sensors and Digital Health Technologies (DHTs)

Modern trials increasingly incorporate continuous biosensors, such as continuous glucose monitors (CGMs), wearable electrocardiogram patches, and digital actigraphy watches measuring sleep-wake patterns. These devices stream millions of data points directly to cloud analytics platforms.

Data Management Challenges: Ingesting high-frequency continuous data streams requires specialized data pipelines, algorithmic noise filtering, and predefined statistical triggers to alert clinical teams to safety anomalies.

Device choice and accessible participation

A personal-device approach and sponsor-provided hardware have different compatibility, privacy, accessibility, support and supply implications. Neither guarantees higher adherence or perfect security. Confirm the intended users can access the tool, the instrument remains suitable across supported configurations, staff know how to report failures, and continuity arrangements preserve reliable data. A device's convenience should not exclude otherwise appropriate participants without evaluation.

A time-locked questionnaire can reduce retrospective back-filling but cannot prove who answered, whether a participant understood the questions or whether the device clock was correct. Distinguish observation time, entry time and transmission time. Direct capture still needs metadata and appropriate review, not an assumption that every digital value is automatically authentic.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9(R1) .